Latrogenic Blepharoptosis: Prevention, Recognition, and Management
Includes a Live Web Event on 01/23/2026 at 12:00 PM (EST)
-
You must log in to register
- Non-member - Free!
- AmSpa Basic Member - Free!
- AmSpa Plus Member - Free!
- AmSpa Plus Employee Member - Free!
- SAPA Plus Member - Free!
Eyelid ptosis following periocular onabotulinumtoxinA (BoNT-A) treatment is a known complication that can be frustrating for both patients and practitioners. Latrogenic blepharoptosis occurs due to local spread of the BoNT-A from the periocular region into the levator palpebrae superioris muscle. Although injectors should have a thorough understanding of the relevant anatomy in order to prevent it, BoNT-A induced ptosis can occur even in the most experienced hands.
Brittony Croasdell, MS, FNP-BC, APRN, CANS
Clinical Director and Co-Owner of Fulcrum Aesthetics and Surgery
Aesthetics and Surgery, a Chicago-based wellness and plastic surgery center specializing in aesthetic medicine, regenerative therapies and advanced surgical care. Internationally recognized for her expertise, Croasdell brings more than a decade of experience in non-surgical facial restoration, regenerative modalities and complication management. Known for blending clinical precision with a deeply personalized, patient-centered approach, Croasdell has become a trusted leader in aesthetic care. At Fulcrum, she leads research initiatives on safety, complication outcomes and innovative regenerative protocols. A published author in peer-reviewed journals and a sought-after international speaker, she frequently presents on facial anatomy, neurotoxin resistance and complication resolution. She also founded CRUX Training Academy, an advanced education platform dedicated to safe, effective and ethical aesthetic training.
